Biomarin Pharmaceutical Inc. (BMRN)
Will BioMarin (BMRN) Beat Estimates Again in Its Next Earnings Report?
BioMarin (BMRN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
2 top value stocks to buy for second half of 2025
The second half of 2025 is fast approaching, and the stock market is promising a crazy ride with some exciting news hitting the headlines.
Is the Options Market Predicting a Spike in BioMarin Pharmaceutical Stock?
Investors need to pay close attention to BioMarin Pharmaceutical stock based on the movements in the options market lately.
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz
BMRN's acquisition of INZY is set to add a late-stage enzyme replacement therapy for a rare genetic condition. The deal is likely to be closed by September.
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why BioMarin Pharmaceutical (BMRN) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
BioMarin's First-Quarter Earnings & Sales Beat Estimates
BMRN reports encouraging first-quarter results. The company reiterates its financial guidance for 2025.
